Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02414269CT.gov Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | — | Active Not Recruiting | — | — | — |
NCT01341496CT.gov Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | — | Terminated | — | — | — |
NCT01313429CT.gov Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pleural Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Memorial Sloan Kettering Cancer Center | P1/2 | CCC · 54 |
| Pembrolizumab | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Icasp9M28Z T Cell Infusions | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Celecoxib | National Cancer Institute (NCI) | P1 | CC |
| Epigenetically Modified Autologous Tumor | National Cancer Institute (NCI) | P1 | CC |
| Allogenic Tumor Cell Vaccine (K562) | National Cancer Institute (NCI) | P1 | CC |
| Fapi-46 | Jonsson Comprehensive Cancer Center | P1 | CC |
| Doxepin | Mayo Clinic | P2 | C |
| mt027 | Suzhou Maximum Bio-tech Co., Ltd. | P1 | NR |
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PembrolizumabMemorial Sloan Kettering Cancer CenterCCC
- Icasp9M28Z T Cell InfusionsMemorial Sloan Kettering Cancer CenterCCC
- CelecoxibNational Cancer Institute (NCI)CC
- Epigenetically Modified Autologous TumorNational Cancer Institute (NCI)CC
- Allogenic Tumor Cell Vaccine (K562)National Cancer Institute (NCI)CC
Citation
Floatz Terminal. Cyclophosphamide in Pleural Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-pleural-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →